Amneal Pharmaceuticals Valuation Multiples

Amneal Pharmaceuticals Overview

About Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Founded

2017

HQ

Employees

8.1K

Website

amneal.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $705M

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Amneal Pharmaceuticals Financials

Amneal Pharmaceuticals reported last 12-month revenue of $3B and EBITDA of $705M.

In the same LTM period, Amneal Pharmaceuticals generated $1B in gross profit, $705M in EBITDA, and $285M in net income.

Amneal Pharmaceuticals P&L

In the most recent fiscal year, Amneal Pharmaceuticals reported revenue of $3B and EBITDA of $688M.

Amneal Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals has current market cap of $4B, and enterprise value of $7B.

Amneal Pharmaceuticals' stock price is $13.91.

Amneal Pharmaceuticals Valuation Multiples

Amneal Pharmaceuticals trades at 2.3x EV/Revenue multiple, and 9.7x EV/EBITDA.

Amneal Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Amneal Pharmaceuticals has market cap of $4B and EV of $7B.

Equity research analysts estimate Amneal Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Amneal Pharmaceuticals has a P/E ratio of 15.6x.

Amneal Pharmaceuticals Margins & Growth Rates

Amneal Pharmaceuticals' revenue in the last 12 month grew by 4%.

Amneal Pharmaceuticals' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Amneal Pharmaceuticals' rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Amneal Pharmaceuticals' rule of X is 30% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Amneal Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Amneal Pharmaceuticals M&A Activity

Amneal Pharmaceuticals acquired XXX companies to date.

Last acquisition by Amneal Pharmaceuticals was on XXXXXXXX, XXXXX. Amneal Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Amneal Pharmaceuticals Investment Activity

Amneal Pharmaceuticals invested in XXX companies to date.

Amneal Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Amneal Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).